PPD OncoLocator: Real-time Understanding of Treatment Patterns in Common Cancers
### That's data smarter.

In a constantly changing data landscape, you need access to data solutions that are efficient, high-quality, and designed to meet your needs. You need smart real-world data. You need sRWD — Smart Real-World Data.

Data smarter, at your service

OncoLocator reveals the latest market trends in the top 10 pharma markets for 25 cancers. We gather treatment data from our global healthcare provider network including the US, EU5, Mexico, Brazil, China, and Japan. Based on "last patient seen," the data includes disease stage and identified biomarker[1] to best understand market fragmentation.

Syndicated collection
US ; Eu4 ; UK, Mexico, Brazil, China ; Japan

Prescription data available for

Bladder	Ovarian
BC HR- HER2+	Pancreatic
BC HR+ HER2-	Prostate - CRPC
BC HR+ HER2+	Prostate - HSPC
BC TNBC	Renal
Biliary tract	SCLC
Cervical	Thyroid
Colorectal	Uterus
cancer	ALL
Endometrial	AML
Esophageal	CLL
Gastric	CML
HCC	HL
Head & Neck	MM
Melanoma	NHL – DLBCL
NSCLC	NHL - FL

Additional countries available
Austria, Belgium, Greece, Poland, Romania, Turkey, Switzerland, South Korea, Taiwan, Argentina, Colombia, Peru

The interactive dashboard provides convenient access to quarterly data which is updated monthly to reflect market dynamics. In addition, with only a 30-day lag, the near-to-current data is timely and, provides enriched sample per line of treatment to ensure robustness for each line.

The OncoLocator dashboard powers deeper insights through multiple viewing options, including:

- Treatment pattern per line of therapy
- Treatment pattern trends per line of therapy
- Top 5 biomarkers testing rate and results per disease
- HCP caseload

Three things set us apart from other patient data collections.

With OncoLocator, you get real-time understanding of treatment patterns with unmatched data relevance.

- Single agnostic methodology – We abstract data from patient health records using the same survey platform across countries to allow you to evaluate and compare key market insights.
- Robust data – Enhanced data collection secures sample distribution across all lines and all cancers. Plus, PPD statisticians and epidemiologists use secondary data to extrapolate data to country populations.

Collected data points include:

- Monthly Patient Data Abstraction
  - Disease stage, type/subtype
  - Current treatment prescribed
  - Platinum sensitivity (specific indications)
  - Use of concomitant radiotherapy (solid tumors)
  - Biomarker tested (top 5)
  - Biomarkers results (top 5)
- Biannually Profiling of HCP
  - Specialty and practice setting
  - HCP caseload by disease, disease stage, and line of therapy
  - Percentage of undiagnosed patients by indication
- Supportive expertise – Gain access to PPD expertise in modelling, biostatistics, epidemiology, and more.

---

[1] Top five biomarker per disease.

Data from

7000+ HCPs
and 157,000+
patient charts
in the top 10

How can you use OncoLocator?

With cancer patient treatment data at your fingertips, the applications and insights are endless.

Gain a global understanding of standard of care to help prioritize unmet therapeutic need

Monitor markets affordably to adjust commercial efforts and product life cycle

Evaluate early phase assets by examining latest standard of care

Stay on top of market dynamics

PRESCRIPTION DATA AVAILABLE FOR THE FOLLOWING CANCERS AND TUMORS	
Bladder	Ovarian
BC HR- HER2+	Pancreatic
BC HR+ HER2-	Prostate - CRPC
BC HR+ HER2+	Prostate - HSPC
BC TNBC	Renal
Biliary tract	SCLC
Cervical	Thyroid
Colorectal cancer	Uterus
Endometrial	ALL
Esophageal	AML
Gastric	CLL
HCC	CML
Head & Neck	HL
Melanoma	MM
NSCLC	NHL - DLBCL

PPD®
Part of Thermo Fisher Scientific